Quarta-Rad, Inc.
0.9000+0.00 (+0%)
Oct 29, 4:00:00 PM EDT · OTC Markets OTCPK · QURT · USD
Key Stats
Market Cap
14.31MP/E (TTM)
-Basic EPS (TTM)
-0.01Dividend Yield
0%Recent Filings
10-Q
Q2 FY2025 results
Quarta-Rad's Q2 FY2025 revenue climbed 132% y/y to $67.3K, driven by Sellavir's $65K in AI consulting services to related parties, while Quarta-Rad's device sales dropped 92% y/y to $2.3K amid supply constraints from the Russian invasion of Ukraine. Gross profit rose to $37.7K, but operating expenses jumped 47% y/y to $124.3K, fueled by $55.7K in stock-based compensation, yielding an operating loss of $86.6K—up 17% y/y—versus a net loss of $72.1K after $13.7K foreign currency gains. YTD revenue doubled 96% y/y to $100.2K, narrowing net loss to $149.5K from $154K, with diluted EPS steady at $(0.01) on 15.9M shares. Cash dwindled to $29.6K after $33.5K operating outflow, no debt but $250K liabilities mostly related-party payables; a $199K note receivable transfer settled obligations. Sellavir's CenterEye AI platform shows early Japan traction. Yet competition in AI call center software poses adoption risks.
10-Q
Q1 FY2025 results
Quarta-Rad posted Q1 FY2025 net sales of $32.9K, up 49.2% y/y from $22.0K, driven by $30.0K from Sellavir's AI services while Quarta-Rad's device sales fell 86.9% y/y to $2.9K amid supply constraints. Gross loss narrowed to $1.4K from $11.8K profit, with operating loss widening to $89.9K (up 43.8% y/y) on $37.1K stock-based compensation, yet net loss improved 15.5% y/y to $77.4K, or $0.00 per diluted share on 15.8M shares. Cash dipped q/q to $49.8K after $13.3K operating outflow, with no capex so free cash flow matched; related-party notes receivable stand at $403.5K, but a $382K working capital deficit persists. Sellavir's CenterEye platform gained Japan traction. Geopolitical risks from the Russian invasion of Ukraine continue to crimp device inventory.
10-K
FY2024 results
Quarta-Rad's FY2024 revenue plunged 79% to $106,797 from $508,316 in 2023, driven by inventory constraints in Quarta-Rad's detection devices and deferred recognition in Sellavir's AI services, yielding a net loss of $216,755 versus prior profit. Quarta-Rad sales fell 79% to $66,797 amid reduced purchases, while Sellavir dropped 79% to $40,000 but pivoted to call center AI innovation. Operating expenses rose 26% to $246,549, fueled by contractor costs, eroding gross profit to $39,685. Cash dwindled to $63,021 with a $260,907 working capital deficit, yet related-party notes provided $46,812 in interest income. No quarterly breakdowns disclosed. Management eyes capital raises and partnerships to fund Sellavir's CenterEye platform. Geopolitical tensions could further disrupt supply chains.
10-Q
Q3 FY2024 results
Quarta-Rad's Q3 FY2024 results show revenue plunging 70% y/y to $18,697, driven by an 86% drop in Quarta-Rad sales to $8,697 amid Russian supply constraints, while Sellavir added $10,000 from a new licensing deal. Gross profit swung to $13,503 from a slim $2,930 last year, but operating expenses climbed 9% to $58,324, yielding a narrower operating loss of $48,821 versus $50,649. Net loss shrank to $2,609, cushioned by a $33,300 foreign currency gain and investment swings, though YTD net loss widened to $156,604 on 81% revenue decline to $69,783 and a $110,561 realized investment loss; EPS holds at -$0.01 with 15.7M shares. Cash dipped to $50,281, with $87,864 used in operations offset by $65,520 from security sales, and no debt but $384,530 in related-party liabilities. Post-quarter, a spin-off of operations is under exploration. Russian sanctions continue to crimp inventory flows.
10-Q
Q2 FY2024 results
Quarta-Rad's Q2 FY2024 results showed revenue of $29,044, down 71.6% y/y from $102,082, while YTD revenue fell 83.0% y/y to $51,086, driven by lower Quarta-Rad device sales and no Sellavir recognition. Gross profit shrank to $10,620 from $52,591 y/y, with operating expenses up 17.5% to $84,562 amid higher general and administrative costs, yielding an operating loss of $73,942 versus $19,380 last year; net loss widened to $62,344, differing from operating by unrealized investment gains and related-party interest. Cash dipped to $63,734, with operating cash use of $34,413 YTD versus generation last year, yet related-party notes receivable stand at $382,342, secured by Thai land. Sellavir eyes AI call center subscriptions for steady revenue. Inventory sourcing shifts to Kazakhstan mitigate Russian sanctions. Controls remain weak.
IPO
Website
Sector
Industry
ARAY
Accuray Incorporated
1.44-0.04
BIO
Bio-Rad Laboratories, Inc.
319.47-10.95
IRMD
iRadimed Corporation
78.31-1.48
MIR
Mirion Technologies, Inc.
29.75+4.56
QDEL
QuidelOrtho Corporation
27.94-0.25
QTIH
QT Imaging Holdings, Inc.
6.95-0.12
QTRX
Quanterix Corporation
5.17-0.31
SRTS
Sensus Healthcare, Inc.
3.21-0.06
TDY
Teledyne Technologies Incorpora
515.33-10.12
UCLE
US Nuclear Corp.
0.09+0.03